Brought to you by 
Avitide closes $7.7mm Series C round
10 Aug 2015
Executive Summary
Avitide Inc. (bioprocess affinity chromatography resins used in biopharmaceutical manufacturing) raised $7.7mm in Series C financing from 11 investors led by NeoMed Management, which contributed a board member, plus returning shareholders Polaris Partners, OrbiMed Advisors, SV Life Sciences, and Borealis Ventures. Avitide will use the money to commercialize its affinity purification technology; the company expects to be profitable within two years.
Deal Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avitide closes $7.7mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice